

IPERION LIMITED

Results for announcement to the market		
Name of issuer	Iperion Limited (NZX: IPR)	
Reporting Period	12 months to 31 March 2026	
Previous Reporting Period	12 months to 31 March 2025	
Currency	NZD	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$0	0%
Total Revenue	\$0	0%
Net profit/(loss) from continuing operations	\$(295)	(35%)
Total net profit/(loss)	\$(295)	(35%)
Interim/Final Dividend		
Amount per Quoted Equity Security	The company does not propose to pay a dividend at this time.	
Imputed amount per Quoted Equity Security	Not applicable	
Record Date	Not applicable	
Dividend Payment Date	Not applicable	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.0001	\$0.0007
A brief explanation of any of the figures above necessary to enable the figures to be understood	Included with this report is the commentary from the Directors and financial statements for the year ended 31 March 2026. The financial statements are in the process of being audited.	
Authority for this announcement		
Name of person authorised to make this announcement	John Cilliers	
Contact person for this announcement	John Cilliers	
Contact phone number	+6 27 242 8485	
Contact email address	john.cilliers@outlook.co.nz	
Date of release through MAP	29 May 2026	

IPERION LIMITED

Preliminary Full Year Result for the Year Ended 31 March 2026.

Dear Shareholders

The Directors of Iperion Limited (“the Company”) are pleased to report its financial results for the year ended 31 March 2026.

Financial Results

The Company reported a net loss attributable to shareholders of \$294,595 for the year. This compares with a net loss attributable to shareholders of \$455,683 for the previous year.

There was no sales income for the year. The improvement in result compared to the previous year is mainly a result of discount received on the fixed outsourced manufacturing plant fee.

There were no manufacturing plant expenses for the year. The vendor agreed to discount the \$400,000 fixed annual fees for the two financial years ending 31 March 2026 and 31 March 2027 in recognition of lower than expected production activity and the plant being partially supported by research grants secured by the operator on the ongoing development in applications for the *Pathoglaze*[®] product.

Administrative expenses for the year were \$294,605 decreasing by \$23,176 on the prior year. Expenses remained mostly in line with the previous year, except for higher stock exchange costs and lower costs on travel in the year.

Operations and Product Development

Work undertaken over the last year has mainly focused on completing the development of *Pathoglaze* infused polymer jute bags used for shipping cocoa and coffee beans. This work is being undertaken in collaboration with a multinational chocolate manufacturer.

The Company continues to work toward securing long term sales agreements. In order to preserve available cash reserves, Directors agreed to defer payment of 50% of directors fees since January 2026, until the Company achieves sufficient sales to deliver a positive cash flow result.

On behalf of the Directors of Iperion the Company extends its thanks to the shareholders for their support of the Company.

Preliminary Statement of Comprehensive Income

For the year ended 31 March 2026

	Unaudited	Audited
	Year	Year
	2026	2025
	\$	\$
Interest Income - financial asset at amortised cost	10	20,382
Outsourced manufacturing plant expenses	-	(150,000)
Administrative expenses	(294,605)	(317,781)
Depreciation, amortisation and impairment	-	(8,284)
Loss before interest and tax	(294,595)	(455,683)
Finance costs	-	-
Loss before income tax	(294,595)	(455,683)
Income tax expense	-	-
Net loss for the period attributable to shareholders	(294,595)	(455,683)
Other comprehensive income	-	-
Total comprehensive loss for the period attributable to shareholders	(294,595)	(455,683)

Preliminary Statement of Financial Position

As at 31 March 2026

	Unaudited Year 2026 \$	Audited Year 2025 \$
Assets		
Current assets		
Cash and cash equivalents	155,492	425,341
GST receivable	1,196	1,384
Income tax receivable (RWT)	7,563	7,563
	164,251	434,288
Non-current assets		
NZX Deposit	20,000	20,000
	20,000	20,000
Total assets	184,251	454,288
Equity and liabilities		
Current liabilities		
Trade and other payables	130,448	105,890
Total liabilities	130,448	105,890
Equity		
Issued capital	5,672,856	5,672,856
Accumulated loss	(5,619,053)	(5,324,458)
Total equity	53,803	348,398
Total equity and liabilities	184,251	454,288

Preliminary Statement of Changes in Equity

For the year ended 31 March 2026

	Unaudited		
	Issued capital \$	Accumulated Loss \$	Total equity \$
As at 1 April 2025	5,672,856	(5,324,458)	348,398
Loss for the year	-	(294,595)	(294,595)
Total comprehensive income	-	(294,595)	(294,595)
At 31 March 2026	5,672,856	(5,619,053)	53,803
As at 1 April 2024	5,672,856	(4,868,775)	804,081
Loss for the year	-	(455,683)	(455,683)
Total comprehensive income	-	(455,683)	(455,683)
At 31 March 2025	5,672,856	(5,324,458)	348,398

Preliminary Statement of Cash Flows

For the year ended 31 March 2026

	Unaudited	Audited
	Year	Year
	2026	2025
	\$	\$
Operating activities		
Interest received	10	20,382
Payments to suppliers	(270,047)	(454,996)
Net GST refunds (paid)/received	188	(2,709)
Income tax paid	-	(7,563)
Income tax refund received	-	12,030
Net cash outflows from operating activities	(269,849)	(432,856)
Investing activities		
Purchase of intangible assets	-	(8,284)
Cash received from maturity of term deposit	-	697,834
Net cash inflows from investing activities	-	689,550
Net increase / (decrease) in cash and cash equivalents	(269,849)	256,694
Cash and cash equivalents at beginning of year	425,341	168,647
Cash and cash equivalents at end of year	155,492	425,341